What the Brexit Transition Period Means for Pharma
The “standstill” transition period begins as the Withdrawal Agreement clears the final hurdle.
Three-and-a-half years since the Brexit vote, the UK has left the EU – with a deal. There was no late drama as the European Parliament approved the Withdrawal Agreement by 621 votes to 49.
The UK now enters a “transition period.” Although the UK will have no MEPs, no Commissioner, and no seat at the EU Council; EU law will continue to apply in the UK. And that means companies can continue UK batch release testing and qualified person (QP) certification; marketing authorization (MA) holders and QPs, and QPPVs can continue to be based in the UK and access EU markets; manufacturing and distribution licences will continue to be recognized by the EU and vice versa, as will inspections; and UK-based firms can continue to apply for MAs via either the centralized or decentralized procedure (1) * published in the Medicine Maker on 11th of February 2020